Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants
We assessed the real‐life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2018-04, Vol.103 (4), p.684-691 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 691 |
|---|---|
| container_issue | 4 |
| container_start_page | 684 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 103 |
| creator | Moustafa, Farès Pesavento, Raffaele di Micco, Pierpaolo González‐Martínez, José Quintavalla, Roberto Peris, Maria‐Luisa Porras, José Antonio Falvo, Nicolas Baños, Pilar Monreal, Manuel |
| description | We assessed the real‐life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio (HR): 3.10; 95% confidence interval (CI): 2.47–3.88), major bleeds (HR: 4.10; 95% CI: 3.38–4.96), and deaths (HR: 9.47; 95% CI: 8.46–10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n = 115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0.18; 95% CI: 0.04–0.79) than those on unfractionated heparin (n = 224) and similar to those (n = 3,172) on low‐molecular‐weight (LMWH) heparin. For long‐term therapy, patients on rivaroxaban (n = 151) had nonsignificantly fewer VTE recurrences (adjusted HR: 0.74; 95% CI: 0.08–1.32) and major bleeds (adjusted HR: 0.41; 95% CI: 0.15–1.15) than those on LMWH (n = 2,071). The efficacy and safety of DOACs were similar to standard therapy. |
| doi_str_mv | 10.1002/cpt.781 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1915884289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1915884289</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3171-9da558dfbe24e889af4c713c599293f11c9074d0ae666606ab67d219dc2a627a3</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotn7gP5DcFGRrkv1KjlJbFQqKVD0uaXbWRrKbmuyi3rx78Tf6S0ytehAcCMNknnkneRHao2RACWHHatEOck7XUJ-mMYuyNE7XUZ8QIiLB4qyHtrx_CGUiON9EPcazPE0y0kdv1yDNx-u70RXgGw_YVvikabWy8r4zsmk91g2-hcZ2Hk_nztYzC-EY7Wt8p9s5lnhsVWjaBl_JVsNy5Ksxelam8zrcD51uwWmJK-vwqXagWnzppPmzaQdtVNJ42P3O2-hmPJoOz6PJ5dnF8GQSqZjmNBKlTFNeVjNgCXAuZJWonMYqFYKJuKJUCZInJZGQhSCZnGV5yagoFZMZy2W8jQ5XugtnHzvwbVFrr8CER0D4ZkEFTTlPGBcBPVihylnvHVTFwulaupeCkmLpfBGcL4Lzgdz_Fu1mNZS_3I_VAThaAU_awMt_OsXwarqU-wQmKo7Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1915884289</pqid></control><display><type>article</type><title>Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants</title><source>Wiley-Blackwell Journals</source><creator>Moustafa, Farès ; Pesavento, Raffaele ; di Micco, Pierpaolo ; González‐Martínez, José ; Quintavalla, Roberto ; Peris, Maria‐Luisa ; Porras, José Antonio ; Falvo, Nicolas ; Baños, Pilar ; Monreal, Manuel</creator><creatorcontrib>Moustafa, Farès ; Pesavento, Raffaele ; di Micco, Pierpaolo ; González‐Martínez, José ; Quintavalla, Roberto ; Peris, Maria‐Luisa ; Porras, José Antonio ; Falvo, Nicolas ; Baños, Pilar ; Monreal, Manuel ; RIETE Investigators ; the RIETE Investigators</creatorcontrib><description>We assessed the real‐life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio (HR): 3.10; 95% confidence interval (CI): 2.47–3.88), major bleeds (HR: 4.10; 95% CI: 3.38–4.96), and deaths (HR: 9.47; 95% CI: 8.46–10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n = 115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0.18; 95% CI: 0.04–0.79) than those on unfractionated heparin (n = 224) and similar to those (n = 3,172) on low‐molecular‐weight (LMWH) heparin. For long‐term therapy, patients on rivaroxaban (n = 151) had nonsignificantly fewer VTE recurrences (adjusted HR: 0.74; 95% CI: 0.08–1.32) and major bleeds (adjusted HR: 0.41; 95% CI: 0.15–1.15) than those on LMWH (n = 2,071). The efficacy and safety of DOACs were similar to standard therapy.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.781</identifier><identifier>PMID: 28675460</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical pharmacology and therapeutics, 2018-04, Vol.103 (4), p.684-691</ispartof><rights>2017 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2017 American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3171-9da558dfbe24e889af4c713c599293f11c9074d0ae666606ab67d219dc2a627a3</citedby><cites>FETCH-LOGICAL-c3171-9da558dfbe24e889af4c713c599293f11c9074d0ae666606ab67d219dc2a627a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcpt.781$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcpt.781$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28675460$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moustafa, Farès</creatorcontrib><creatorcontrib>Pesavento, Raffaele</creatorcontrib><creatorcontrib>di Micco, Pierpaolo</creatorcontrib><creatorcontrib>González‐Martínez, José</creatorcontrib><creatorcontrib>Quintavalla, Roberto</creatorcontrib><creatorcontrib>Peris, Maria‐Luisa</creatorcontrib><creatorcontrib>Porras, José Antonio</creatorcontrib><creatorcontrib>Falvo, Nicolas</creatorcontrib><creatorcontrib>Baños, Pilar</creatorcontrib><creatorcontrib>Monreal, Manuel</creatorcontrib><creatorcontrib>RIETE Investigators</creatorcontrib><creatorcontrib>the RIETE Investigators</creatorcontrib><title>Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>We assessed the real‐life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio (HR): 3.10; 95% confidence interval (CI): 2.47–3.88), major bleeds (HR: 4.10; 95% CI: 3.38–4.96), and deaths (HR: 9.47; 95% CI: 8.46–10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n = 115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0.18; 95% CI: 0.04–0.79) than those on unfractionated heparin (n = 224) and similar to those (n = 3,172) on low‐molecular‐weight (LMWH) heparin. For long‐term therapy, patients on rivaroxaban (n = 151) had nonsignificantly fewer VTE recurrences (adjusted HR: 0.74; 95% CI: 0.08–1.32) and major bleeds (adjusted HR: 0.41; 95% CI: 0.15–1.15) than those on LMWH (n = 2,071). The efficacy and safety of DOACs were similar to standard therapy.</description><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LAzEQhoMotn7gP5DcFGRrkv1KjlJbFQqKVD0uaXbWRrKbmuyi3rx78Tf6S0ytehAcCMNknnkneRHao2RACWHHatEOck7XUJ-mMYuyNE7XUZ8QIiLB4qyHtrx_CGUiON9EPcazPE0y0kdv1yDNx-u70RXgGw_YVvikabWy8r4zsmk91g2-hcZ2Hk_nztYzC-EY7Wt8p9s5lnhsVWjaBl_JVsNy5Ksxelam8zrcD51uwWmJK-vwqXagWnzppPmzaQdtVNJ42P3O2-hmPJoOz6PJ5dnF8GQSqZjmNBKlTFNeVjNgCXAuZJWonMYqFYKJuKJUCZInJZGQhSCZnGV5yagoFZMZy2W8jQ5XugtnHzvwbVFrr8CER0D4ZkEFTTlPGBcBPVihylnvHVTFwulaupeCkmLpfBGcL4Lzgdz_Fu1mNZS_3I_VAThaAU_awMt_OsXwarqU-wQmKo7Y</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Moustafa, Farès</creator><creator>Pesavento, Raffaele</creator><creator>di Micco, Pierpaolo</creator><creator>González‐Martínez, José</creator><creator>Quintavalla, Roberto</creator><creator>Peris, Maria‐Luisa</creator><creator>Porras, José Antonio</creator><creator>Falvo, Nicolas</creator><creator>Baños, Pilar</creator><creator>Monreal, Manuel</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants</title><author>Moustafa, Farès ; Pesavento, Raffaele ; di Micco, Pierpaolo ; González‐Martínez, José ; Quintavalla, Roberto ; Peris, Maria‐Luisa ; Porras, José Antonio ; Falvo, Nicolas ; Baños, Pilar ; Monreal, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3171-9da558dfbe24e889af4c713c599293f11c9074d0ae666606ab67d219dc2a627a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moustafa, Farès</creatorcontrib><creatorcontrib>Pesavento, Raffaele</creatorcontrib><creatorcontrib>di Micco, Pierpaolo</creatorcontrib><creatorcontrib>González‐Martínez, José</creatorcontrib><creatorcontrib>Quintavalla, Roberto</creatorcontrib><creatorcontrib>Peris, Maria‐Luisa</creatorcontrib><creatorcontrib>Porras, José Antonio</creatorcontrib><creatorcontrib>Falvo, Nicolas</creatorcontrib><creatorcontrib>Baños, Pilar</creatorcontrib><creatorcontrib>Monreal, Manuel</creatorcontrib><creatorcontrib>RIETE Investigators</creatorcontrib><creatorcontrib>the RIETE Investigators</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moustafa, Farès</au><au>Pesavento, Raffaele</au><au>di Micco, Pierpaolo</au><au>González‐Martínez, José</au><au>Quintavalla, Roberto</au><au>Peris, Maria‐Luisa</au><au>Porras, José Antonio</au><au>Falvo, Nicolas</au><au>Baños, Pilar</au><au>Monreal, Manuel</au><aucorp>RIETE Investigators</aucorp><aucorp>the RIETE Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2018-04</date><risdate>2018</risdate><volume>103</volume><issue>4</issue><spage>684</spage><epage>691</epage><pages>684-691</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>We assessed the real‐life use of direct oral anticoagulants (DOACs) in patients with venous thromboembolism (VTE) and exclusion criteria for randomized trials. From 2013 to 2016, 3,578 of 18,853 patients (19%) had exclusion criteria. Irrespective of which anticoagulant was chosen, they had more VTE recurrences (hazard ratio (HR): 3.10; 95% confidence interval (CI): 2.47–3.88), major bleeds (HR: 4.10; 95% CI: 3.38–4.96), and deaths (HR: 9.47; 95% CI: 8.46–10.6) than those without exclusion criteria. During initial therapy, no patient with exclusion criteria on DOACs (n = 115) recurred, but those on rivaroxaban bled less often (adjusted HR: 0.18; 95% CI: 0.04–0.79) than those on unfractionated heparin (n = 224) and similar to those (n = 3,172) on low‐molecular‐weight (LMWH) heparin. For long‐term therapy, patients on rivaroxaban (n = 151) had nonsignificantly fewer VTE recurrences (adjusted HR: 0.74; 95% CI: 0.08–1.32) and major bleeds (adjusted HR: 0.41; 95% CI: 0.15–1.15) than those on LMWH (n = 2,071). The efficacy and safety of DOACs were similar to standard therapy.</abstract><cop>United States</cop><pmid>28675460</pmid><doi>10.1002/cpt.781</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2018-04, Vol.103 (4), p.684-691 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1915884289 |
| source | Wiley-Blackwell Journals |
| title | Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral Anticoagulants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T18%3A32%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%E2%80%90life%20Use%20of%20Anticoagulants%20in%20Venous%20Thromboembolism%20With%20a%20Focus%20on%20Patients%20With%20Exclusion%20Criteria%20for%20Direct%20Oral%20Anticoagulants&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Moustafa,%20Far%C3%A8s&rft.aucorp=RIETE%20Investigators&rft.date=2018-04&rft.volume=103&rft.issue=4&rft.spage=684&rft.epage=691&rft.pages=684-691&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.781&rft_dat=%3Cproquest_cross%3E1915884289%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1915884289&rft_id=info:pmid/28675460&rfr_iscdi=true |